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1. Introduction 
Chronic low back pain is a common, debilitating, and costly health problem (Centers for 
Disease Control and Prevention, 2001; Collins et al., 2005; Mapel et al., 2004; Vogt et al., 
2005). The prevalence of chronic low back pain is higher in women and in whites versus 
blacks (Andersson, 1999; Mapel et al., 2004). Although the risk of chronic low back pain 
increases with age (Mapel et al., 2004), back pain remains the most common cause of 
disability in adults aged <45 years (Andersson, 1999).  
Treatment guidelines issued in the United States (Chou et al., 2007) and Europe (Airaksinen 
et al, 2006) both state that back pain becomes chronic if it persists for ≥12 weeks. United 
States guidelines also distinguish between acute (<4 weeks) and subacute (4–<12 weeks) 
back pain (Chou et al., 2007). The 12-week threshold for classifying back pain as chronic 
makes sense given data suggesting that 80% to 95% of patients with disabling back pain can 
return to normal activities within 12 weeks, with less certain outcomes thereafter 
(Andersson, 1999).  
Treatments for chronic low back pain include nonpharmacologic therapies (eg, exercise, 
lifestyle modification), which are discussed elsewhere in this book. First-line 
pharmacotherapies include acetaminophen, nonsteroidal anti-inflammatory drugs 
(NSAIDs), weak opioids, and strong opioids. Each of these therapies, including opioids, 
may be initiated during the acute phase of back pain, depending on the severity of pain 
(Chou et al., 2007). However, the course of chronic low back pain may be protracted 
(Andersson, 1999), meaning patients may require treatment over years or decades. It is 
therefore important that pharmacological treatments be effective and as safe as possible both 
in the short term and in patients requiring long-term treatment. Acetaminophen is a well-
tolerated first-line pharmacotherapy but has limited efficacy (Zhang et al., 2010) and high-
dose, long-term use is associated with hepatic toxicity (Watkins et al., 2006). NSAIDs have 
better efficacy than acetaminophen but have well-known risks of gastrointestinal (Boers et 
al., 2007; Gabriel et al., 1991; Hippisley-Cox et al., 2005), cardiovascular (Antman et al., 2007; 
Caldwell et al., 2006; Hippisley-Cox & Coupland, 2005; Kearney et al., 2006; Motsko et al., 
2006), and other systemic adverse effects that increase with age, dose, and duration of use. 
The serotonin norepinephrine reuptake inhibitor (SNRI) duloxetine has received US Food 
and Drug Administration (FDA) approval for the treatment of musculoskeletal pain such as 
chronic low back pain (Cymbalta® Delayed-Release Capsules, 2010). Duloxetine has only 
modest efficacy (Skljarevski et al., 2010a; Skljarevski et al., 2009), is associated with 
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systematic adverse events (Skljarevski et al., 2010a; Skljarevski et al., 2009), and may also 
interact with other analgesics, most notably certain opioids (Smith, 2009).  
Opioids have the greatest efficacy of any oral therapy for relieving pain but also have 
significant risk of adverse events and potential for pharmacokinetic drug interactions 
(Malhotra et al., 2001; Tulner et al., 2008) and carry a substantial risk of addiction and abuse. 
Chronic opioid therapy requires long-term monitoring for treatment compliance.  
This chapter will review guideline recommendations and clinical evidence for 
pharmacotherapies available for the management of chronic low back pain.  
2. Review of guidelines for chronic low back pain and clinical evidence for 
pharmacotherapies 
2.1 Multimodal approach to therapy 
United States guidelines for the management of chronic low back pain recommend that 
effective pharmacotherapy be administered in conjunction with self-care options (eg, 
application of heat, continued activity, adoption of physical fitness regimens, use of a 
medium-firm mattress, lifestyle modifications) (Airaksinen et al., 2006; Chou et al., 2007). 
Nonpharmacologic therapies are discussed in detail elsewhere in this book. For patients not 
responding to medication and self-care, clinicians should employ other nonpharmacologic 
options, including intensive interdisciplinary rehabilitation, exercise therapy, acupuncture, 
massage therapy, spinal manipulation, yoga, cognitive behavioral therapy, and progressive 
relaxation (Airaksinen et al., 2006; Chou et al., 2007). 
2.2 Acetaminophen 
United States Guidelines for the management of chronic low back pain recommend 
acetaminophen as a first-line therapy for mild to moderate pain (Chou et al., 2007); the 
recommendations are based on modest efficacy and overall favorable tolerability in patients 
with osteoarthritis. European guidelines do not recommend acetaminophen (Airaksinen et 
al., 2006). 
Randomized controlled trials of acetaminophen for chronic low back pain are lacking. Both 
US and European guidelines acknowledge that acetaminophen has been less effective than 
oral NSAIDs for osteoarthritis pain (Airaksinen et al., 2006; Chou et al., 2007), and effect 
sizes for acetaminophen calculated by the Osteoarthritis Research Society International are 
below the threshold for a clinically meaningful analgesia (Zhang et al., 2010). 
Acetaminophen is not as safe as it was once believed to be, particularly for a chronic 
condition such as chronic low back pain that may require treatment for many years and may 
also require dose escalation as the disease progresses over time. At doses >4 g/d, 
acetaminophen is known to cause liver enzyme increases >3-fold greater than the upper 
limit of normal in healthy volunteers (Watkins et al., 2006). The FDA is currently 
considering lowering the maximum recommended dose to 3.25 g/day (Kuehn, 2009). In the 
United States, acetaminophen is the leading cause of acute liver failure (Chun et al., 2009).  
Overdose of acetaminophen may be accidental (Camidge et al., 2003; Larson et al., 2005), 
resulting from patients taking too much without realizing there is a dosage ceiling, or from 
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patients taking a product that combines a narcotic with acetaminophen and then 
augmenting it with additional acetaminophen (Larson et al., 2005). Overdose may also be 
deliberate (Camidge et al., 2003; Larson et al., 2005). Despite its reputation as a safe drug, 
acetaminophen is among the drugs implicated most frequently in suicide attempts 
(Camidge et al., 2003; Larson et al., 2005). Also, thought not typically believed to carry 
substantial potential for pharmacokinetic interactions, acetaminophen-associated liver 
failure is significantly associated with alcohol abuse and antidepressant use (Larson et al., 
2005). 
2.3 Nonsteroidal anti-inflammatory drugs 
A Cochrane review of 65 randomized controlled trials found evidence that NSAIDs are 
effective for the management of chronic low back pain pain, but effect sizes were indicative 
of only a small treatment effect (Roelofs et al., 2008). The evidence presented in this 
Cochrane review suggested that different NSAIDs, including cyclooxygenase–2 inhibitors, 
show similar efficacy in patients with chronic low back pain.  
Evidence from meta-analyses provide evidence that NSAIDs are moderately more effective 
than acetaminophen (Lee et al., 2004; Roelofs et al., 2008), and chronic low back pain 
guidelines also state that NSAIDs are more effective (Airaksinen et al., 2006; Chou et al., 
2007). In patients with osteoarthritis, effect sizes for NSAIDs are substantially higher than 
with acetaminophen but nonetheless correspond to a small treatment effect (Zhang et al., 
2010). 
Nonsteroidal anti-inflammatory drugs are associated with well-known risks of 
gastrointestinal (Boers et al., 2007; Gabriel et al., 1991; Hippisley-Cox et al., 2005), 
cardiovascular (Antman et al., 2007; Caldwell et al., 2006; Hippisley-Cox & Coupland, 2005; 
Juni et al., 2004; Kearney et al., 2006; Motsko et al., 2006), and renal (Barkin & Buvanendran, 
2004; Evans et al., 1995) adverse events. Hepatic adverse events have been reported 
infrequently (Rostom et al., 2005; Rubenstein & Laine, 2004), and are certainly less common 
than with acetaminophen. NSAIDs have been associated with potentially clinically 
meaningful increases in blood pressure (Forman et al., 2005; Johnson et al., 1994; Pavlicevic 
et al., 2008), probably both through direct effects (Forman et al., 2005; Johnson et al., 1994) 
and adverse pharmacokinetic interactions with diuretics and angiotensin-converting 
enzyme inhibitors (Pavlicevic et al., 2008). Drug interactions of NSAIDs with 
antihypertensives (angiotensin-converting enzyme inhibitors, diuretics), selective serotonin 
reuptake inhibitors (SSRIs), and corticosteroids (American Geriatrics Society, 2009; Malhotra 
et al., 2001; Tulner et al., 2008) are common. Ibuprofen can nullify the cardioprotective 
effects of aspirin (Gengo et al., 2008). Gastrointestinal bleeding events may occur in patients 
receiving an NSAID with warfarin (Cheetham et al., 2009), an SSRI, or a corticosteroid 
(American Geriatrics Society, 2009). Proton pump inhibitors administered as 
gastroprotection in NSAID-treated patients can block the cardioprotective effects of 
clopidogrel (Ho et al., 2009; Juurlink et al., 2009). 
Cyclooxygenase-2 inhibitors have been associated with fewer adverse events than 
nonselective agents (Roelofs et al., 2008), and in particular have shown improved 
gastrointestinal tolerability (Singh et al., 2006). In a 12-week, 13,000 patient trial, the 
occurrence of abdominal pain, dyspepsia, diarrhea, headache, and nausea was reported in 
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2% to 5% of patients treated with celecoxib and 3% to 6% of those treated with naproxen or 
diclofenac (Singh et al., 2006). Confirmed gastrointestinal bleeding events were also less 
frequent with celecoxib compared with nonselective agents, but occurred in 1% of patients 
compared with 2.1% treated with the nonselective agents.  
Given their risk/benefit ratio, guidelines for the treatment of chronic low back pain 
(Airaksinen et al., 2006; Chou et al., 2007) and osteoarthritis (Zhang et al., 2007; Zhang et al., 
2008) recommend that oral NSAIDs be administered for the shortest period possible at the 
lowest effective dose. Guidelines for the management of chronic pain in the elderly suggest 
that regular oral NSAID use should be avoided if possible (American Geriatrics Society, 
2009). 
2.4 Topical therapies 
United States guidelines for the management of chronic low back pain do not recommend 
topical therapies. European guidelines recommend only capsaicin plaster for short-term 
therapy (<3 wk) in patients with chronic low back pain (Airaksinen et al., 2006).  
2.4.1 The lidocaine 5% patch 
The lidocaine 5% patch has US approval only for the management of postherpetic neuralgia 
(LIDODERM®, 2010), particularly with allodynia (Attal et al., 2010). However, the lidocaine 
5% patch has also shown efficacy in patients with chronic lower back pain (Galer et al., 2004; 
Gimbel et al., 2005). In a 6-week open-label trial, 71 patients with acute/subacute (n=11), 
short-term chronic (n=17), or long-term chronic (n=43) nonradicular back pain applied up to 
4 patches to the maximal area of pain (Galer et al., 2004). All patient subgroups reported 
significant improvements in scores on the Neuropathic Pain Scale. In a second 6-week open-
label study, 131 patients with subacute (n=21), short-term chronic (n=33), and long-term 
chronic (n=77) back pain reported significant mean improvements in scores on the Brief 
Pain Inventory (Gimbel et al., 2005) and significant improvements in the Brief Pain 
Inventory item for interference with quality of life. Beck Depression Inventory scores also 
improved significantly. Approximately two thirds of patients and investigators reported 
being Satisfied or Very Satisfied with treatment. 
Application of up to 4 lidocaine 5% patches daily results in peak systemic lidocaine 
concentrations <200 ng/mL, or >7-fold less than the concentration of >1500 ng/mL required 
to produce cardiac effects and 20-fold less than the threshold concentration for toxic effects 
(Gammaitoni et al., 2003). Consistent with low systemic exposure, the most common 
adverse events reported in a trial of the lidocaine 5% patch in patients with chronic low back 
pain were mild to moderate skin and subcutaneous tissue reactions (eg, rash, pruritus, 
dermatitis, erythema, edema). Treatment-related systemic adverse events were relatively 
uncommon and included dizziness (4%), headache (2%), and nausea (2%–3%) (Gammaitoni 
et al., 2003). 
2.4.2 The capsaicin 8% patch 
In a double-blind, randomized trial, 320 patients with chronic low back pain were assigned 
to apply the capsaicin 8% patch or placebo patch once daily for 3 weeks (Frerick et al., 2003). 
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The capsaicin 8% patch was associated with a 42% reduction in pain assessed using the 
Arhus low back rating scale versus a 31% reduction with placebo. Sixty-seven percent of the 
capsaicin 8% patch group and 49% of the placebo group met response criteria, defined as a 
≥30% reduction in pain. Though statistically significant, these differences compared with 
placebo are very modest. These results were similar to those obtained with a similar 
capsaicin 8% patch in a similarly designed trial (Keitel et al., 2001). The most common 
adverse events were application site warmth or itching, although inflammatory contact 
eczema, urticaria, small hemorrhagic spots, vesiculation, and dermatitis have been reported 
in a small number of patients (Frerick et al., 2003; Keitel et al., 2001). Given modest efficacy 
and generally good tolerability, the capsaicin 8% patch may only be useful as adjunctive 
therapy or as monotherapy in a small subgroup of patients. 
2.4.3 Topical nonsteroidal anti-inflammatory drugs 
Topical NSAIDs produce dramatically lower systemic NSAID concentrations compared 
with oral NSAIDs (Kienzler et al., 2010) and are recommended as a first-line therapy in 
patients with osteoarthritis of the knees or hands (Zhang et al., 2007; Zhang et al., 2008), 
particularly the elderly (American Geriatrics Society, 2009). However, no chronic low back 
pain guidelines recommend topical NSAIDs and chronic low back pain is not an approved 
indication for either of the two topical NSAID formulations used in the United States: 
diclofenac sodium 1% gel (Voltaren® Gel 1%, 2007) and diclofenac sodium 1.5% in 45.5% 
dimethyl sulfoxide solution (Pennsaid®, 2009). Neither formulation has been evaluated in 
patients with chronic low back pain.  
Topical diclofenac diethylamine 1.16% gel and an indomethacin plaster were evaluated in 64 
patients with mild to moderate, nonsurgical chronic low back pain (Waikakul et al., 1996). 
Both formulations provided statistically significant improvements in pain and function; 
however, topical NSAIDs have not been evaluated in clinical trials since this 1996 study. 
2.5 Serotonin-norepinephrine reuptake inhibitors 
Duloxetine has shown modest efficacy in two 12-week trials (Skljarevski et al., 2010a; 
Skljarevski et al., 2009) and in a 41-week open-label study (Skljarevski et al., 2010b). Active 
treatment was superior to placebo in both 12-week trials when a 30% improvement in pain 
was defined as a positive response (Skljarevski et al., 2010a; Skljarevski et al., 2009) but only 
in 1 trial when a 50% improvement was defined as a positive response (Skljarevski et al., 
2010a). Given modest efficacy, duloxetine may be a helpful adjunctive therapy (discussed 
below). 
2.6 Weak opioids  
The weak opioids codeine, hydrocodone, and propoxyphene have not been studied 
extensively in patients with chronic low back pain. A single 1976 study of propoxyphene 
showed efficacy in patients with chronic low back pain (Baratta, 1976) and a 1998 study of 
an extended release formulation of codeine combined with acetaminophen demonstrated 
efficacy similar to tramadol (Muller et al., 1998). Hydrocodone has not been studied in 
patient with chronic low back pain. Nonetheless, a meta-analysis showed that weak opioids 
do not have a clear efficacy advantage compared with oral NSAIDs or tricyclic 
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antidepressants (Furlan et al., 2006). Several safety issues limit use of weak opioids. These 
agents are commonly combined with acetaminophen, imposing a dosage ceiling on their use 
(Victor et al., 2009). Codeine has been associated with a high rate of constipation. Moreover, 
though a weak opioid, propoxyphene is associated with more potent respiratory and 
cardiovascular depression than are strong opioids (Barkin et al., 2006; Ulens et al., 1999). 
2.7 Combination weak opioid-norepinephrine reuptake inhibitors 
A Cochrane review of 3 trials found that tramadol is more effective than placebo for treating 
pain and functional impairment (Deshpande et al., 2007). It should be observed that 2 of the 
3 trials analyzed in the Cochrane review evaluated products combining tramadol with 
acetaminophen (Peloso et al., 2004; Ruoff et al., 2003). Although pure opioids theoretically 
have no analgesic dosage ceiling, the presence of acetaminophen imposes a dosage ceiling 
on the product because acetaminophen is hepatotoxic above a daily dose of 4 g (Watkins et 
al., 2006). Tramadol is not a pure opioid agonist but rather also has serotonergic effects that 
limit the recommended daily dose to 300 mg (Ultram ER®, 2009). Serotonergic effects of 
tramadol increase the risk of serotonin syndrome in patients receiving other serotonergic 
drugs, and must not be combined with SNRIs, SSRIs, and tricyclic antidepressants (Ultram 
ER®, 2009). 
Two 6-week trials found that tramadol monotherapy was less effective than the selective 
cyclooxygenase-2 inhibitor celecoxib (O'Donnell et al., 2009). Likewise, tramadol was found 
to be no more effective than extended-release codeine, even though tramadol has the 
additional noradrenergic mechanism of action. The most common adverse events reported 
in the 3 trials of tramadol with or without acetaminophen were typical opioid effects, 
including nausea (8.7%–13%), headache (4.7%–6.6%), somnolence (9%–12.4%), dizziness 
(7.5%–10.8%), dry mouth (6%–8.1%), vomiting (6%), and constipation (10.2%–11.2%) (Peloso 
et al., 2004; Ruoff et al., 2003; Schnitzer et al., 2000).  
Tramadol relies on the cytochrome P450 enzyme 2D6 for metabolism to its active metabolite, 
O-desmethyltramadol, giving it potential for pharmacokinetic interaction with drugs 
metabolized via this pathway. Five to 15% of the white population is classified as having 
either rapid or slow cytochrome P450 enzyme 2D6 metabolizers, meaning that some patients 
will have insufficient or increased sensitivity to both analgesic and adverse effects of the 
drug (Smith, 2009). Collectively, tramadol appears to offer no efficacy advantage compared 
with weak opioids despite its secondary norepinephrine reuptake inhibitor activity. 
A second weak opioid-SNRI combination, tapentadol, differs from tramadol in several 
important respects. Tapentadol is metabolized via glucuronidation and therefore lacks the 
potential for pharmacokinetic interaction and variability response observed with tramadol 
(Kneip et al., 2008). Its noradrenergic effects are more potent than its serotonergic effects 
(Tzschentke et al., 2007), theoretically reducing the risk of serotonergic adverse events, 
although in the United States tapentadol has an FDA “black box” warning against its 
combined use with SSRIs or SNRIs. Analgesic effects of SNRIs are attributed primarily to 
the noradrenergic effects (Max et al., 1992); hence, reduced activity with respect to 
serotonergic function decreases adverse events without compromising analgesic efficacy.  
In a prospective, randomized, double-blind, trial, 981 patients with chronic low back pain 
received tapentadol 100 to 250 mg/d, oxycodone controlled release, or placebo for a 3-week 
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titration period followed by a 12-week maintenance period. Tapentadol and oxycodone 
produced similar, statistically significant improvements in pain compared with placebo. 
Tapentadol was associated with a lower occurrence compared with oxycodone of total 
adverse events, constipation, nausea, and vomiting. A pooled analysis of this study and two 
12-week studies of patients with osteoarthritis (n=2010) demonstrated that tapentadol was 
as effective as oxycodone controlled release in improving mean pain intensity, but more 
people treated with tapentadol experienced 30% and 50% reductions in pain (Lange et al., 
2010). Only tapentadol was associated with significant improvements in quality of life, 
which may reflect superior tolerability with tapentadol. Tapentadol exhibited a superior 
gastrointestinal tolerability compared with oxycodone (Lange et al., 2010). A subsequent 
subanalyses of these trials found that the lower incidence of constipation with tapentadol 
(13%–18%) compared with oxycodone (27%–36%) should be associated with a lower rate of 
work absenteeism and productivity loss in tapentadol-treated patients, based on previous 
research correlating constipation with productivity (Cepeda et al., 2011).  
A limitation of studies comparing tapentadol with oxycodone controlled release was the 
dosage ranges used. Patients assigned to oxycodone received a dose of 20 to 50 mg twice 
daily (Lange et al., 2010), which is well below the effective dose for many patients. All 
patients, including opioid-experienced patients, were started on oxycodone 10 mg. The 
maximum dose of 50 mg is much less than the maximum doses reported in oxycodone trials 
(Rauck et al., 2006a). Nonetheless, if patients were underdosed with respect to analgesia, 
they also would be expected to have more adverse events at higher, more effective doses. 
Thus, at optimal oxycodone doses with respect to analgesia, differences in tolerability 
favoring tapentadol might be even more pronounced. 
Given statistically significant efficacy compared with placebo, a trial of a weak opioid-SNRI 
combination drug before prescribing a strong opioid may be a valuable option in many 
patients. 
2.8 Strong opioids: Efficacy 
Despite increasing use in patients with chronic noncancer pain in recent years, opioids have 
not been studied extensively in patients with chronic low back pain. A 2007 Cochrane 
review of opioids for chronic low back pain (Deshpande et al., 2007) included only 1 trial of 
a strong opioid (Jamison et al., 1998). This 1998 trial found that oxycodone immediate 
release and oxycodone combined with morphine extended release were both significantly 
superior to naproxen in patients with moderate to severe chronic low back pain (Jamison et 
al., 1998). Similarly a 2006 meta-analysis of opioids in chronic noncancer pain included the 
same single study of oxycodone in chronic low back pain and reached the same conclusion 
(Furlan et al., 2006). A 2011 meta-analysis included 4 additional studies, one of tramadol, 2 
of oxymorphone extended release, and 1 of oxycodone with ultra-low-dose naltrexone 
(Kuijpers et al., 2011). 
Oxymorphone extended release was evaluated in two 12-week randomized controlled trials 
in opioid-naive and opioid-experienced patients with moderate to severe chronic low back 
pain (Hale et al., 2007; Katz et al., 2007). Results from these studies demonstrated that use of 
a flexible, individualized titration schedule will allow the majority (60% in the 2 studies 
combined) of patients to be titrated to an effective, generally well-tolerated opioid dose 
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(Peniston & Gould, 2009). The trial in opioid-naïve patients demonstrated that the lowest 
available doses of oxymorphone extended release can be administered safety in patients 
who have never received an opioid. In contrast, some long-acting opioids are not 
appropriate as a starting medication for opioid-naïve patients; for example, the fentanyl 
transdermal patch and hydromorphone OROS (discussed following) (Duragesic®, 2009; 
EXALGO complete prescribing information, 2010). The trial of oxymorphone extended 
release in opioid-experienced patients demonstrated that patients who grow tolerant to one 
opioid formulation can be successfully transitioned to another opioid with ostensibly the 
same mechanism of action and experience adequate pain relief with acceptable tolerability.  
This finding is important given the clinical observation that patients requiring long-term 
opioid therapy typically require successive trials of different opioids to find one that works, 
and that even after finding the right opioid, will frequently grow tolerant to the initial 
opioid and need to be rotated to another opioid to maintain analgesia or avoid adverse 
events that emerge with dose escalation (Grilo et al., 2002; Mercadante & Bruera, 2006; 
Quang-Cantagrel et al., 2000). It is important to have multiple effective opioids from which 
to choose an initial agent and have options for switching as tolerance develops (Slatkin, 
2009). It remains to be determined whether after switching from an initial opioid to another, 
responsiveness to the original opioid will return over time to allow a switch back if tolerance 
to the second opioid emerges. In both opioid-naïve and –experienced patients, 
oxymorphone extended release analgesia and functional improvement remained 
significantly superior to placebo for the entire 12-week treatment period without dose 
escalation (Hale et al., 2007; Katz et al., 2007). Of patients successfully titrated and 
randomized to oxymorphone extended release, 69% completed 12 weeks of treatment 
(Peniston & Gould, 2009). 
Oxycodone has been formulated with ultra-low-dose naltrexone in order to minimize 
adverse events (eg, respiratory depression, constipation, physical dependence) (Amass et al., 
2000; Chindalore et al., 2005; Webster et al., 2006). In a double-blind trial, 719 patients with 
moderate to severe chronic low back pain received placebo, oxycodone immediate release 4 
times daily, oxycodone with naltrexone 4 times daily, or oxycodone plus naltrexone twice 
daily for 12 weeks (Webster et al., 2006). All patients initiated treatment with a total daily 
oxycodone dose of 10 mg and were titrated over a period of 1 to 6 weeks to a dose that 
provided effective analgesia with acceptable tolerability or to a maximum daily dose of 80 
mg. All oxycodone regimens provided significantly superior analgesia compared with 
placebo. The mean daily oxycodone dose was 12% lower with the oxycodone plus 
naltrexone regimens than with oxycodone. Compared with oxycodone administered 4 times 
daily, oxycodone plus naltrexone twice daily was associated with 44% less constipation, 33% 
less somnolence, and 51% less pruritus. Upon abrupt opioid discontinuation, the severity of 
withdrawal symptoms assessed using the Short Opiate Withdrawal Scale was 55.8% less 
with oxycodone plus naltrexone twice daily compared with oxycodone 4 times daily 
(Webster et al., 2006). 
In a randomized, open-label trial, 392 patients with chronic low back pain were randomized 
to an effective, generally well-tolerated dose of once-daily morphine extended release or 
twice-daily oxycodone controlled release (Rauck et al., 2006a). Patients then entered an 8-
week evaluation phase comparing the 2 treatments. As in the previous trials, use of a 
flexible titration schedule allowed 67.9% of patients (morphine extended release, 65.0%; 
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oxycodone controlled release, 70.9%) to be titrated successful. Once-daily morphine 
extended-release capsules provided significantly better analgesia with a lower morphine-
equivalent daily dose compared with oxycodone twice daily (Rauck et al., 2006a). Sleep 
quality was significantly better with once-daily morphine, and rescue ibuprofen use was 
significantly less compared with twice-daily oxycodone. During a 4-month extension phase, 
patients receiving once-daily morphine continued to experience lower pain intensity and 
greater improvements in sleep quality (Rauck et al., 2006b). 
A second once-daily opioid formulation, hydromorphone OROS, was also associated with 
statistically significant improvements in pain, quality of life measures, and sleep quality 
during a 6-week open-label trial (Wallace et al., 2007) and 6-month open-label follow-up 
(Wallace & Thipphawong, 2010). A clinical trial of hydromorphone OROS demonstrated 
that administration with ethanol does not result in premature release of hydromorphone 
from the capsule, a phenomenon referred to as “dose-dumping” (Sathyan et al., 2008). This 
is important because a previous formulation of hydromorphone extended release exhibited 
dose-dumping, resulting in its withdrawal from the US market (FDA asks Purdue Pharma 
to withdraw Palladone, 2005). 
The efficacy and tolerability of fentanyl transdermal patch were demonstrated in open-label 
trials lasting 1 month (Simpson et al., 1997), 3 months (Lee et al., 2011), and 13 months 
(Allan et al., 2005), respectively. In the 13-month study (Allan et al., 2005), 673 patients with 
moderate to severe chronic low back pain ingested morphine sustained release once every 
12 hours or applied a single fentanyl patch every 72 hours. Both treatments provided 
similar, significant analgesia throughout the study. Each opioid formulation was associated 
with typical opioid-associated adverse events such as constipation, nausea, vomiting, 
dizziness, diarrhea, and somnolence. Constipation was significantly less frequent with the 
fentanyl patch (52%) than with morphine sustained release (65%). The 3-month trial enrolled 
1576 patients with severe, treatment-refractory chronic low back pain. Fentanyl provided 
significant improvements in measures of pain, function, and sleep quality. It should be 
noted, however, that <1% of patients enrolled in this trial had received a strong opioid as 
their prior medication; hence, the results support the use of transdermal fentanyl in patients 
with severe refractory pain but do not distinguish fentanyl from other opioids. Of note, the 
use of fentanyl transdermal patch for opioid-naïve patients in this study is contrary to the 
products’ approved use.(Duragesic®, 2009) In contrast, studies of oxymorphone (Hale et al., 
2007), oxycodone controlled release, and morphine extended release (Rauck et al., 2006a), 
and hydromorphone OROS (Wallace et al., 2007) have demonstrated efficacy in patients 
with chronic low back pain that was moderate to severe despite previous opioid therapy. 
Fentanyl may offer advantages over oral opioids for patients with compliance issues, 
including those with problems chewing or swallowing. Fentanyl clearance appears to be 
affected very little by renal failure (Dean, 2004) or hepatic cirrhosis (Haberer et al., 1982) 
impairment, making it an option that may be used with caution in these populations. 
However, fentanyl patch should not be administered to opioid-naïve patients because there 
is a significant risk of respiratory depression even with the lowest available fentanyl patch 
dose, 25 μg/hour (Duragesic®, 2009).  
In a randomized, double-blind crossover study, 79 patients with chronic low back pain 
applied a 7-day buprenorphine transdermal patch or placebo patch for 4 weeks of treatment 
before crossing over to the alternate therapy for an additional 4 weeks (Gordon et al., 2010). 
www.intechopen.com
 Low Back Pain Pathogenesis and Treatment 
 
124 
Patients began treatment with the 5 µg/h patch and were titrated with each successive 
application to the maximum tolerated dose (5, 10, or 20 µg/h). Fifty-four of 73 (74%) patients 
completed 4 weeks of treatment with buprenorphine patch. Mean reduction in pain (100-
mm Visual Analog Scale) was 39.5% in the buprenorphine group and 29.8% in the placebo 
group, which was statistically significant. Improvements in Pain Disability Index scores 
were significant compared with baseline but not compared with placebo. 
2.8.1 Summary of efficacy data 
Flexible titration allows for successful titration in the majority of opioid-treated patients. The 
availability of formulations administered twice daily, daily, every 3 days, or once weekly 
allows for individualized treatment of patients to optimize treatment compliance. Studies of 
long-acting oxymorphone, oxycodone, morphine, hydromorphone, fentanyl, and 
buprenorphine confirm the analgesic efficacy in patients with chronic low back pain. 
Patients who do not respond or who grow tolerant to an opioid therapy can be transitioned 
to a second opioid with the same mechanism of action. The impact of opioids on functional 
status is variable. 
2.8.2 Summary of safety data 
The most common adverse events during opioid therapy include constipation (41%), nausea 
(32%), somnolence/sedation (29%), vomiting (15%), dizziness (20%), itching (15%), dry 
mouth (13%), and headache (8%) (Kalso et al., 2004). Approximately one quarter of patients 
discontinue clinical trials owing to adverse events (Kalso et al., 2004). Flexible titration 
reduces adverse events and allows the majority of patients to be titrated to an effective dose 
(Peniston & Gould, 2009; Rauck et al., 2006a). In 2 trials of oxymorphone extended release, 
nearly two thirds (348 of 575; 60.5%) of patients were successfully titrated to a well-tolerated 
oxymorphone extended release dose. Opioid-naïve patients were started at a low dose (10 
mg/d) and opioid-experienced patients were transitioned from their previous opioid using 
published conversion ratios. Titration was gradual (5–10 mg every 3–7 days) and at 
investigators discretion. Discontinuations due to adverse events during titration (18.4%) 
were lower than typically observed in opioid trials (Peniston & Gould, 2009).  
Similarly, in a trial comparing morphine extended release with oxycodone controlled 
release, use of a flexible titration schedule allowed 67.9% of patients (morphine extended 
release, 65.0%; oxycodone controlled release, 70.9%) to be titrated successfully (Rauck et al., 
2006a). Discontinuations due to adverse events during the titration period were reported in 
18.7% of patients treated with morphine extended release and 14.3% treated with oxycodone 
controlled release.  
All opioids have a potential for clinically significant pharmacodynamic drug interactions, 
particularly when combined with drugs that cause respiratory depression (eg, barbiturates) 
or central nervous system depression (eg, alcohol, benzodiazepines), but opioids differ in 
their potential for pharmacokinetic drug interactions. The majority of opioids are 
metabolized by the cytochrome P450 system and have potential for pharmacokinetic 
interaction with many drugs (Smith, 2009). Exceptions to this are morphine (Coffman et al., 
1997), oxymorphone (Adams et al., 2005; OPANA® ER, 2010), and hydromorphone 
(Hydromorphone-HP Injection 10 mg 2008), each of which primarily undergo phase 2 
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metabolism by glucuronidation. Selection of an opioid that is not metabolized via 
cytochrome P450 enzymes is important when there is a known cytochrome P450 
pharmacokinetic interaction with a concurrent medication but may also be desirable in 
patients likely to be prescribed multiple medications, such as the elderly, patients with 
psychiatric illness, and patients with multiple medical problems (Smith & Bruckenthal, 
2010). 
The labels for all strong opioids recommend against concurrent use with alcohol because of 
the potential for clinically meaningful additive pharmacodynamic effects (Dilaudid® Oral 
Liquid and Dilaudid® Tablets, 2008; Duragesic®, 2009; Kadian®, 2007; OPANA® ER, 2010; 
OxyContin®, 2010). Additive effects when opioids are administered with alcohol are to be 
distinguished from the phenomenon of dose-dumping described previously with reference 
to hydromorphone extended release. Clinical trials have demonstrated the integrity of 
hydromorphone OROS (Sathyan et al., 2008) and morphine extended release (Barkin et al., 
2009; Johnson et al., 2008) when administered with 240 mL of 4% to 40% ethanol. 
Coadministration of oxymorphone extended release with 240 mL of 4% and 20% ethanol, 
corresponding to modest and moderate alcohol consumption, did not cause premature 
release of oxymorphone from the extended release tablet (Fiske et al., 2011). Oxymorphone 
extended release administered with a 240 mL solution of 40% ethanol resulted in potentially 
clinically meaningful increases in oxymorphone maximum concentration (Fiske et al., 2011). 
It should be noted, however, that the 40% ethanol solution corresponds to heavy alcohol 
intake, which is to be avoided in any opioid-treated patient. 
2.8.3 Minimize abuse potential 
Before initiating opioid therapy, physicians should take a thorough patient history that 
includes a history of prior or current substance abuse or psychiatric disease, as well as 
accurate documentation of current prescribed medications. Patients should undergo a 
physical examination sufficient to confirm the diagnosis of chronic low back pain and 
determine pain intensity and the extent of disability. This will help establish that a request 
for an analgesic is legitimate rather than drug-seeking behavior (Cone & Caplan, 2009). 
Patients should also be screened for abuse risk using validated screening instruments such 
as the Opioid Risk Tool (Webster & Webster, 2005), Current Opioid Misuse Measure (Butler 
et al., 2007), and the revised Screener and Opioid Assessment for Patients with Pain (Butler 
et al., 2008). 
Opioid therapy should be conducted using a plan that includes controlled substance 
agreements, frequent random urine drug testing, and confirmatory urine drug testing (Cone 
& Caplan, 2009; Manchikanti et al., 2008). Screening should be conducted in all patients, 
regardless of perceived risk of abuse (Gourlay et al., 2005). In patients believed to be at 
increased risk, selection of an opioid that does not produce metabolites that are identical to 
other opioids may simplify urine drug screening (Cone & Caplan, 2009). Positive test results 
for patients prescribed buprenorphine, fentanyl, oxymorphone, tapentadol, and tramadol 
will not be confused by the presence of multiple opioids.  
Drug companies are currently attempting to develop formulations that incorporate obstacles 
to abuse. Most of these technologies are designed to resist common methods by which 
abusers tamper with an oral opioid formulation to facilitate intranasal or intravenous abuse 
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(Katz, 2008). Tamper-resistant opioids include formulations with physical barriers to 
crushing, chewing, and dissolution; formulations with sequestered antagonists that 
neutralize opioid effects if the formulation is chewed or crushed; and formulations with 
sequestered noxious components that are released if the opioid is chewed or crushed.  
At present, 2 tamper-resistant formulations have received FDA approval. OXECTA® is a 
short-acting formulation of oxycodone with sequestered ingredients that are released if the 
opioid is chewed or crushed (OXECTA®, 2011). In addition to oxycodone, the formulation 
contains several ingredients that may cause irritation if swallowed or inhaled, including 
colloidal silicon dioxide (Amorim et al., 2010), crospovidone (Lowe et al., 2006), 
microcrystalline cellulose (Teshima et al., 2002), and sodium lauryl sulfate (Engel et al., 
2008).  
Oxycodone controlled release has also been reformulated in a polymer matrix that resists 
crushing or chewing (US Food and Drug Administration, 2010) and becomes a viscous gel if 
the product is immersed in fluid (Schneider et al., 2010). The value of tamper-resistant 
formulations of oxycodone and other opioids is likely to be limited unless all opioids are 
reformulated with this purpose in mind. Otherwise, the availability of one opioid in a 
tamper-resistant formulation may simply divert abusers to another opioid that has not been 
reformulated. Since the approval of reformulated oxycodone, oxycodone has seen a decline 
in abuse, with a corresponding increase in oxymorphone abuse (Goodnough, 2011; Nassau 
County executive: abuse of painkiller Opana is growing, 2011). Oxymorphone extended 
release is not currently available in a tamper resistant formulation, although such a 
formulation is in development. 
2.9 Adjunctive therapies 
Tricyclic antidepressants are recommended in both US and European guidelines for the 
management of chronic low back pain. Two systematic reviews concluded that tricyclic 
antidepressants have modest beneficial effects on pain but limited effects on functional 
status (Salerno et al., 2002; Staiger et al., 2003).  
Duloxetine can be administered safely with NSAIDs, acetaminophen, and opioids that do 
not undergo cytochrome P450 metabolism, such as oxymorphone, hydromorphone, 
fentanyl, or morphine (Smith, 2009). Because it is a substrate and moderate inhibitor of the 
cytochrome P450 enzyme 2D6, pharmacokinetic interactions with oxycodone, tramadol, and 
codeine are possible (Cymbalta® Delayed-Release Capsules, 2010). Given its modest efficacy 
(discussed previously), addition of duloxetine to ongoing opioid or NSAID therapy may be 
a useful alternative to switching to another medication or increasing the dose of an opioid or 
NSAID. Duloxetine may be of particular value in chronic pain patients with comorbid 
depression. In an open-label pilot study (Karp et al., 2010), duloxetine administered to 
patients with comorbid chronic low back pain and major depression improved both pain 
and depression. 
Guidelines in the United States state that gabapentin has modest efficacy in patients with 
chronic low back pain (Chou et al., 2007), whereas the European guidelines state that there 
is no convincing evidence (Airaksinen et al., 2006). Other anticonvulsants are not 
recommended. Benzodiazepines have been recommended for use as muscle relaxants for 
short-term therapy in both US and European guidelines (Airaksinen et al., 2006; Chou et al., 
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2007). These anxiolytics have a high risk of addiction and abuse, and their combined use 
with opioids is of particular concern (Rich & Webster, 2011). 
2.10 Invasive therapies 
In US guidelines, epidural steroid injection is recommended for patients with persistent 
chronic low back pain and signs of radiculopathy or spinal stenosis (Chou et al., 2007). 
European guidelines state that epidural injections have insufficient evidence to support a 
recommendation (Airaksinen et al., 2006). Intrathecal opioids (morphine or methadone) 
have been administered for severe chronic low back pain, almost always following failed 
back surgery (Noble et al., 2010). Though effective, intrathecal delivery of opioids has been 
associated with granuloma formation (Allen et al., 2006). Neither intrathecal nor epidural 
opioid infusion is recommended in US or European treatment guidelines.  
United States guidelines state that transcutaneous nerve stimulation has not been proven 
effective for chronic low back pain (Chou et al., 2007). European guidelines state that 
clinicians may consider percutaneous electrical nerve stimulation or neuroflexotherapy 
(Airaksinen et al., 2006). European guidelines also recommend against local facet nerve 
blocks, trigger point injections, and spinal cord stimulation (Airaksinen et al., 2006). Surgery 
is not recommended unless other treatment options have been unsuccessful for 1 year (US) 
(Chou et al., 2007) or 2 years (Europe) (Airaksinen et al., 2006). 
3. Treatment algorithm 
Treatment recommendations based on the clinical data provided previously are 
summarized in Figure 1. Patients with mild to moderate chronic low back pain should begin 
pharmacotherapy with acetaminophen or an NSAID. Acetaminophen has limited efficacy, 
poses risks of liver failure with cumulative/escalating use, is not recommended in patients 
with hepatic impairment, and should be given cautiously to patients with depression or at 
risk of substance abuse because of its documented use by patients wishing to inflict self-
harm. Patients with dementia may have difficulties reporting pain, so clinicians should be 
sure that patients are not in need of more potent analgesia. 
Oral NSAIDs are more effective than acetaminophen but still have only modest efficacy, 
making their use best reserved for mild to moderate pain that does not respond to 
acetaminophen. NSAIDs should be administered for the shortest period of time at the 
lowest effective dose, and are not generally recommended in older patients and those with 
current or a history of gastrointestinal bleeding or significant cardiovascular or renal 
comorbidities. Caution is recommended when administering NSAIDs in patients taking 
SSRIs, corticosteroids, warfarin, cardioprotective aspirin (ibuprofen only), diuretics and 
angiotensin-converting enzyme inhibitors. An oral NSAID with a gastroprotective proton 
pump inhibitor should not be administered to patients receiving clopidogrel.  
Topical lidocaine patch is recommended for the treatment of chronic low back pain in 
Europe but not the United States. Lidocaine patch has shown efficacy in patients with 
chronic low back pain. Capsaicin plasters have shown only very modest efficacy and cause 
localized burning that limits tolerability. Capsaicin patches are not recommended, and their 
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localized numbing effect is better achieved using a lidocaine patch. Topical NSAIDs have 
few data supporting their use for chronic low back pain and require further investigation of 
their potential value for this indication. 
 
Reprinted from PostGrad Med, 122, Altman RD, Smith HS. Opioid Therapy for Osteoarthritis and 
Chronic Low Back Pain, 87-97, 2010, with permission from JTE Multimedia.  
Fig. 1. Treatment algorithm for patients with chronic low back pain. COX2= cyclooxygenase 
-2, NSAID=nonsteroidal anti-inflammatory drug, PGE2= prostaglandin E2, PPI=proton 
pump inhibitor.  
There are limited data supporting the use of tramadol in patients with chronic low back 
pain. Tramadol may be administered in combination products that include 
acetaminophen. This imposes a dosage ceiling on the product that may limit use of 
tramadol. There are more robust data for tapentadol; however, it is unclear whether this is 
because of a difference in efficacy or to it having been studied more rigorously. Both 
tramadol and tapentadol are associated with typical opioid adverse events, but 
gastrointestinal adverse events are less frequent than with strong opioids. Though less 
potent than strong opioids, tapentadol may be a safer option for patients who may benefit 
from an opioid but want to reduce risks. As noradrenergic agents may be administered as 
adjunctive therapy for chronic low back pain, tapentadol affords an opportunity to utilize 
2 analgesic mechanisms in a single pill.  
Opioids have a growing body of evidence supporting their use in patients with chronic low 
back pain. Much of these data have been published after the most recent US and European 
guidelines were developed. Trials of long-acting formulations of oxycodone, morphine, 
oxymorphone, hydromorphone, and buprenorphine have shown good efficacy with 
acceptable tolerability in patients with chronic low back pain. Starting with a low dose in 
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opioid-naïve patients and titrating slowly based on individual response increases the 
likelihood that treatment will be tolerated. Opioid-experienced patients can be transitioned 
to a new opioid at a dose slightly lower than that considered equipotent based on 
established conversion ratios. Titration should proceed slowly based on individual 
response. Opportunities for twice-daily, once-daily, or once-weekly dosing allow clinicians 
to tailor treatment in order to maximum compliance. In patients receiving multiple 
medications, it may be advisable to prescribe an opioid that is not metabolized by the 
cytochrome P450 enzyme system. Opioid therapy needs to be predicated on a full history, 
screening for abuse potential, and agreement to regular monitoring for treatment 
compliance and signs of abuse. Drugs that do not produce other opioids as metabolites will 
simplify urine drug screening.  
Epidural corticosteroid injections should be reserved for patients with persistent pain that 
does not respond adequately to rehabilitation and pharmacotherapy. Surgery should be 
reserved for patients with prolonged, disabling, nonresponsive pain. Discussions of these 
more invasive therapies are reserved for elsewhere in this book.  
4. Conclusion 
Though ideally chronic low back pain would respond to self-management techniques, 
pharmacotherapy remains an essential component of treatment without which patients 
cannot maintain their levels of activity. There are clinical data that suggest uncontrolled 
pain can interfere with physical therapy, whereas improvements in pain are accompanied 
by improvements in function and response to therapy (Gross et al., 2008; Schein et al., 
2008; Soin et al., 2008; Teske et al., 2008). Sufficient analgesia may be necessary to allow 
patients to effectively participate in a physical therapy program. The perceived choice 
facing clinicians is between medications with limited efficacy, but relatively benign 
adverse events profiles, and more potent analgesics with more substantial risks of adverse 
events or drug abuse.  
Acetaminophen and NSAIDs have modest efficacy, but acetaminophen has significant risks 
of hepatic adverse events and NSAIDs with gastrointestinal, cardiovascular, renal and other 
systemic adverse events. Duloxetine has moderate efficacy comparable to acetaminophen or 
NSAIDs and is useful as an adjunctive medication. Tramadol and tapentadol offer 
advantages of opioid agonism paired with norepinephrine reuptake inhibition, but should 
not be combined with SNRIs or SSRIs. Opioids offer the greatest efficacy of available 
pharmacologic therapies, and, although opioids have significant risks of abuse, overdose, 
and distressing gastrointestinal adverse effects (nausea, constipation), they have a safety 
advantage over NSAIDs with respect to cardiovascular adverse events and gastrointestinal 
bleeding. The American Heart Association has stated that opioids may be preferred over 
NSAIDs in patients with significant cardiovascular risk (Antman et al., 2007). 
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